Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 835

1.
2.

Conformational Variants of the Individual HLA-I Antigens on Luminex Single Antigen Beads Used in Monitoring HLA Antibodies: Problems and Solutions.

Jucaud V, Ravindranath MH, Terasaki PI.

Transplantation. 2017 Apr;101(4):764-777. doi: 10.1097/TP.0000000000001420.

PMID:
27495776
3.

Prevalence and Clinical Impact of Donor-Specific Alloantibody Among Intestinal Transplant Recipients.

Cheng EY, Everly MJ, Kaneku H, Banuelos N, Wozniak LJ, Venick RS, Marcus EA, McDiarmid SV, Busuttil RW, Terasaki PI, Farmer DG.

Transplantation. 2017 Apr;101(4):873-882. doi: 10.1097/TP.0000000000001391.

PMID:
27490417
4.

Dynamics and epitope specificity of anti-human leukocyte antibodies following renal allograft nephrectomy.

Lachmann N, Schönemann C, El-Awar N, Everly M, Budde K, Terasaki PI, Waiser J.

Nephrol Dial Transplant. 2016 Aug;31(8):1351-9. doi: 10.1093/ndt/gfw041. Epub 2016 Apr 19.

PMID:
27190369
5.

Significance of the differences in the prevalence of anti-HLA antibodies in matched pairs of mother's and cord blood.

Ravindranath MH, Jucaud V, Maehara CY, Terasaki PI.

Immunol Lett. 2016 Feb;170:68-79. doi: 10.1016/j.imlet.2015.11.016. Epub 2015 Dec 22.

PMID:
26721232
6.

Complement-fixing antibodies against denatured HLA and MICA antigens are associated with antibody mediated rejection.

Cai J, Terasaki PI, Zhu D, Lachmann N, Schönemann C, Everly MJ, Qing X.

Exp Mol Pathol. 2016 Feb;100(1):45-50. doi: 10.1016/j.yexmp.2015.11.023. Epub 2015 Nov 23.

PMID:
26615783
7.

Proposed Diagnostic Criteria for Chronic Antibody-Mediated Rejection in Liver Allografts.

O'Leary JG, Cai J, Freeman R, Banuelos N, Hart B, Johnson M, Jennings LW, Kaneku H, Terasaki PI, Klintmalm GB, Demetris AJ.

Am J Transplant. 2016 Feb;16(2):603-14. doi: 10.1111/ajt.13476. Epub 2015 Oct 15.

8.

Onset and progression of de novo donor-specific anti-human leukocyte antigen antibodies after BK polyomavirus and preemptive immunosuppression reduction.

Dieplinger G, Everly MJ, Briley KP, Haisch CE, Bolin P, Maldonado AQ, Kendrick WT, Kendrick SA, Morgan C, Terasaki PI, Rebellato LM.

Transpl Infect Dis. 2015 Dec;17(6):848-58. doi: 10.1111/tid.12467.

PMID:
26442607
9.

Serum antibodies to human leucocyte antigen (HLA)-E, HLA-F and HLA-G in patients with systemic lupus erythematosus (SLE) during disease flares: Clinical relevance of HLA-F autoantibodies.

Jucaud V, Ravindranath MH, Terasaki PI, Morales-Buenrostro LE, Hiepe F, Rose T, Biesen R.

Clin Exp Immunol. 2016 Mar;183(3):326-40. doi: 10.1111/cei.12724. Epub 2015 Dec 16.

10.

The Monospecificity of Novel Anti-HLA-E Monoclonal Antibodies Enables Reliable Immunodiagnosis, Immunomodulation of HLA-E, and Upregulation of CD8+ T Lymphocytes.

Ravindranath MH, Terasaki PI, Pham T, Jucaud V.

Monoclon Antib Immunodiagn Immunother. 2015 Jun;34(3):135-53. doi: 10.1089/mab.2014.0096.

PMID:
26090591
11.

Impact of IgG3 subclass and C1q-fixing donor-specific HLA alloantibodies on rejection and survival in liver transplantation.

O'Leary JG, Kaneku H, Banuelos N, Jennings LW, Klintmalm GB, Terasaki PI.

Am J Transplant. 2015 Apr;15(4):1003-13. doi: 10.1111/ajt.13153. Epub 2015 Mar 13.

12.

Risk Stratification of Human Leukocyte Antigen Class II Donor Specific Antibody Positive Patients by Immunoglobulin G Subclasses.

Taniguchi M, Rebellato LM, Briley KP, Haisch CE, Bolin P, Banuelos N, Hopfield J, Terasaki PI, Everly MJ.

Clin Transpl. 2015;31:293-301.

PMID:
28514591
13.
14.

Pre-existing anti-HLA antibodies negatively impact survival of pediatric aplastic anemia patients undergoing HSCT.

Zhu H, He J, Cai J, Yuan X, Jiang H, Luo C, Wang J, Luo C, Pan Z, Terasaki PI, Ding L, Chen J.

Clin Transplant. 2014 Nov;28(11):1225-33. doi: 10.1111/ctr.12450. Epub 2014 Sep 19.

PMID:
25123053
15.

Acute liver allograft antibody-mediated rejection: an inter-institutional study of significant histopathological features.

O'Leary JG, Michelle Shiller S, Bellamy C, Nalesnik MA, Kaneku H, Jennings LW, Isse K, Terasaki PI, Klintmalm GB, Demetris AJ.

Liver Transpl. 2014 Oct;20(10):1244-55. doi: 10.1002/lt.23948.

16.

Association of anti-human leukocyte antigen and anti-angiotensin II type 1 receptor antibodies with liver allograft fibrosis after immunosuppression withdrawal.

Ohe H, Uchida Y, Yoshizawa A, Hirao H, Taniguchi M, Maruya E, Yurugi K, Hishida R, Maekawa T, Uemoto S, Terasaki PI.

Transplantation. 2014 Nov 27;98(10):1105-11. doi: 10.1097/TP.0000000000000185.

PMID:
24914568
17.

Changes in successive measures of de novo donor-specific anti-human leukocyte antigen antibodies intensity and the development of allograft dysfunction.

Dieplinger G, Everly MJ, Rebellato LM, Haisch CE, Briley KP, Bolin P, Kendrick WT, Kendrick SA, Morgan C, Harland RC, Terasaki PI.

Transplantation. 2014 Nov 27;98(10):1097-104. doi: 10.1097/TP.0000000000000190.

PMID:
24911039
19.

Donor-specific alloantibodies are associated with fibrosis progression after liver transplantation in hepatitis C virus-infected patients.

O'Leary JG, Kaneku H, Jennings L, Susskind BM, Terasaki PI, Klintmalm GB.

Liver Transpl. 2014 Jun;20(6):655-63. doi: 10.1002/lt.23854.

20.
21.

The role of donor-specific HLA alloantibodies in liver transplantation.

O'Leary JG, Demetris AJ, Friedman LS, Gebel HM, Halloran PF, Kirk AD, Knechtle SJ, McDiarmid SV, Shaked A, Terasaki PI, Tinckam KJ, Tomlanovich SJ, Wood KJ, Woodle ES, Zachary AA, Klintmalm GB.

Am J Transplant. 2014 Apr;14(4):779-87. doi: 10.1111/ajt.12667. Epub 2014 Mar 1.

22.

Impact of the presence and duration of donor-specific antibodies on renal function.

Hoshino J, Everly MJ, Kaneku H, Ubara Y, Takaichi K, Terasaki PI.

Transplant Proc. 2014 Jan-Feb;46(1):75-80. doi: 10.1016/j.transproceed.2013.09.032.

PMID:
24507029
23.

Impact of IgM and IgG3 anti-HLA alloantibodies in primary renal allograft recipients.

Everly MJ, Rebellato LM, Haisch CE, Briley KP, Bolin P, Kendrick WT, Kendrick SA, Morgan C, Maldonado AQ, Harland RC, Terasaki PI.

Transplantation. 2014 Mar 15;97(5):494-501. doi: 10.1097/01.TP.0000441362.11232.48.

PMID:
24487396
24.

Antibody-mediated rejection as a contributor to previously unexplained early liver allograft loss.

O'Leary JG, Kaneku H, Demetris AJ, Marr JD, Shiller SM, Susskind BM, Tillery GW, Terasaki PI, Klintmalm GB.

Liver Transpl. 2014 Feb;20(2):218-27. doi: 10.1002/lt.23788. Epub 2014 Jan 2.

25.

Improved Long-Term Survival in Kidney Transplant Recipients with Donor-Specific HLA Antibodies After Mycophenolic Acid Escalation.

Rebellato LM, Parker K, Everly MJ, Briley KP, Kendrick W, Kendrick S, Haisch CE, Terasaki PI, Bolin P.

Clin Transpl. 2014:137-42.

PMID:
26281138
26.

Gastric cancer progression may involve a shift in HLA-E profile from an intact heterodimer to β2-microglobulin-free monomer.

Sasaki T, Ravindranath MH, Terasaki PI, Freitas MC, Kawakita S, Jucaud V.

Int J Cancer. 2014 Apr 1;134(7):1558-70. doi: 10.1002/ijc.28484. Epub 2013 Dec 11.

27.

Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodies.

Taniguchi M, Rebellato LM, Cai J, Hopfield J, Briley KP, Haisch CE, Catrou PG, Bolin P, Parker K, Kendrick WT, Kendrick SA, Harland RC, Terasaki PI.

Am J Transplant. 2013 Oct;13(10):2577-89. doi: 10.1111/ajt.12395. Epub 2013 Aug 13.

28.

Trends and characteristics in early glomerular filtration rate decline after posttransplantation alloantibody appearance.

Wu P, Everly MJ, Rebellato LM, Haisch CE, Briley KP, Bolin P, Kendrick WT, Kendrick SA, Morgan C, Harland RC, Terasaki PI.

Transplantation. 2013 Nov 27;96(10):919-25. doi: 10.1097/TP.0b013e3182a289ac.

PMID:
23912173
29.

Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation.

O'Leary JG, Kaneku H, Jennings LW, Bañuelos N, Susskind BM, Terasaki PI, Klintmalm GB.

Liver Transpl. 2013 Sep;19(9):973-80. doi: 10.1002/lt.23687. Epub 2013 Jul 26.

30.

HLA class II DQA and DQB epitopes: recognition of the likely binding sites of HLA-DQ alloantibodies eluted from recombinant HLA-DQ single antigen cell lines.

El-Awar N, Nguyen A, Almeshari K, Alawami M, Alzayer F, Alharbi M, Sasaki N, Terasaki PI.

Hum Immunol. 2013 Sep;74(9):1141-52. doi: 10.1016/j.humimm.2013.05.013. Epub 2013 Jun 10.

PMID:
23756161
31.

Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.

Wu P, Jin J, Everly MJ, Lin C, Terasaki PI, Chen J.

Clin Biochem. 2013 Oct;46(15):1389-93. doi: 10.1016/j.clinbiochem.2013.05.053. Epub 2013 May 29.

PMID:
23726814
32.

De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients.

Kaneku H, O'Leary JG, Banuelos N, Jennings LW, Susskind BM, Klintmalm GB, Terasaki PI.

Am J Transplant. 2013 Jun;13(6):1541-8. doi: 10.1111/ajt.12212.

33.

The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes.

Freitas MC, Rebellato LM, Ozawa M, Nguyen A, Sasaki N, Everly M, Briley KP, Haisch CE, Bolin P, Parker K, Kendrick WT, Kendrick SA, Harland RC, Terasaki PI.

Transplantation. 2013 May 15;95(9):1113-9. doi: 10.1097/TP.0b013e3182888db6.

PMID:
23514959
34.

The clinical impact of humoral immunity in pediatric renal transplantation.

Chaudhuri A, Ozawa M, Everly MJ, Ettenger R, Dharnidharka V, Benfield M, Mathias R, Portale A, McDonald R, Harmon W, Kershaw D, Vehaskari VM, Kamil E, Baluarte HJ, Warady B, Li L, Sigdel TK, Hsieh SC, Dai H, Naesens M, Waskerwitz J, Salvatierra O Jr, Terasaki PI, Sarwal MM.

J Am Soc Nephrol. 2013 Mar;24(4):655-64. doi: 10.1681/ASN.2012070663. Epub 2013 Feb 28.

35.

Humoral theory of transplantation: some hot topics.

Cai J, Qing X, Tan J, Terasaki PI.

Br Med Bull. 2013;105:139-55. doi: 10.1093/bmb/lds037. Epub 2013 Feb 7. Review.

PMID:
23396319
36.

Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.

Everly MJ, Rebellato LM, Haisch CE, Ozawa M, Parker K, Briley KP, Catrou PG, Bolin P, Kendrick WT, Kendrick SA, Harland RC, Terasaki PI.

Transplantation. 2013 Feb 15;95(3):410-7. doi: 10.1097/TP.0b013e31827d62e3.

PMID:
23380861
37.

Therapeutic preparations of IVIg contain naturally occurring anti-HLA-E antibodies that react with HLA-Ia (HLA-A/-B/-Cw) alleles.

Ravindranath MH, Terasaki PI, Pham T, Jucaud V, Kawakita S.

Blood. 2013 Mar 14;121(11):2013-28. doi: 10.1182/blood-2012-08-447771. Epub 2013 Jan 10.

38.

Alloantibody and autoantibody monitoring predicts islet transplantation outcome in human type 1 diabetes.

Piemonti L, Everly MJ, Maffi P, Scavini M, Poli F, Nano R, Cardillo M, Melzi R, Mercalli A, Sordi V, Lampasona V, Espadas de Arias A, Scalamogna M, Bosi E, Bonifacio E, Secchi A, Terasaki PI.

Diabetes. 2013 May;62(5):1656-64. doi: 10.2337/db12-1258. Epub 2012 Dec 28.

39.

Novel biomarker combination predicts long-term allograft outcome.

Cail J, Huang W, Terasaki PI, Everly MJ, Briley KP, Haisch CE, Bolin P, Kendrick WT, Kendrick SA, Morgan C, Harland RC, Rebellato LM.

Clin Transpl. 2013:319-24.

PMID:
25095524
40.

Anti-HLA-E monoclonal antibodies reacting with HLA-la and lb alleles like IVIg as potential IVIg-immunomimetics: an evolving therapeutic concept.

Ravindranath MH, Zhu D, Pham T, Jucaud V, Hopfield J, Kawakita S, Terasaki PI.

Clin Transpl. 2013:293-305. Review.

PMID:
25095521
41.

Predicting operational tolerance in pediatric living-donor liver transplantation by absence of HLA antibodies.

Waki K, Sugawara Y, Mizuta K, Taniguchi M, Ozawa M, Hirata M, Nozawa M, Kaneko J, Takahashi K, Kadowaki T, Terasaki PI, Kokudo N.

Transplantation. 2013 Jan 15;95(1):177-83. doi: 10.1097/TP.0b013e3182782fef.

PMID:
23232368
42.

Detection of antibodies against major histocompatibility complex class I-related chain A in long-term renal graft recipients.

Li Z, Luo M, Qiu J, Liu Y, Fan Y, Jahr FM, Cai J, Terasaki PI.

Exp Clin Transplant. 2012 Jun;10(3):239-42.

43.

Using donor-specific antibodies to monitor the need for immunosuppression.

Hoshino J, Kaneku H, Everly MJ, Greenland S, Terasaki PI.

Transplantation. 2012 Jun 15;93(11):1173-8. doi: 10.1097/TP.0b013e31824f3d7c.

PMID:
22592887
44.

Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation.

Kaneku H, O'Leary JG, Taniguchi M, Susskind BM, Terasaki PI, Klintmalm GB.

Liver Transpl. 2012 Aug;18(8):984-92. doi: 10.1002/lt.23451.

45.

Courage and character, leaders and legends: an interview with Paul I. Terasaki, PhD. Interview by Linda Ohler.

Terasaki PI.

Prog Transplant. 2012 Mar;22(1):4-5. No abstract available.

PMID:
22489437
46.

A personal perspective: 100-year history of the humoral theory of transplantation.

Terasaki PI.

Transplantation. 2012 Apr 27;93(8):751-6. doi: 10.1097/TP.0b013e3182483713.

PMID:
22453870
47.

Augmentation of anti-HLA-E antibodies with concomitant HLA-Ia reactivity in IFNγ-treated autologous melanoma cell vaccine recipients.

Ravindranath MH, Selvan SR, Terasaki PI.

J Immunotoxicol. 2012 Jul-Sep;9(3):282-91. doi: 10.3109/1547691X.2011.645582. Epub 2012 Jan 30.

PMID:
22283601
48.

Durability of antibody removal following proteasome inhibitor-based therapy.

Everly MJ, Terasaki PI, Trivedi HL.

Transplantation. 2012 Mar 27;93(6):572-7. doi: 10.1097/TP.0b013e31824612df.

PMID:
22262128
49.

Antibodies to HLA-E may account for the non-donor-specific anti-HLA class-Ia antibodies in renal and liver transplant recipients.

Ravindranath MH, Pham T, Ozawa M, Terasaki PI.

Int Immunol. 2012 Jan;24(1):43-57. doi: 10.1093/intimm/dxr094. Epub 2011 Dec 20.

PMID:
22190577
50.

The state of therapy for removal of alloantibody producing plasma cells in transplantation.

Everly MJ, Terasaki PI.

Semin Immunol. 2012 Apr;24(2):143-7. doi: 10.1016/j.smim.2011.08.014. Epub 2011 Dec 5. Review.

PMID:
22153981

Supplemental Content

Loading ...
Support Center